SLC5A2 and type 2 diabetes mellitus: Furthermore, regarding acute variations in cf-PWV levels, we cannot exclude that this different behavior might be due to the different SGLT2 selectivity of the two drugs; These findings are relevant to clinical practice, as they highlight the importance of selecting the appropriate SGLT2 inhibitor treatment to optimize hemodynamic and metabolic outcomes in patients with T2D or related conditions.